Osteoporosis causes bones to become brittle.  When osteoporosis is severe, minimal accidents, like a fall or even sneezing can cause affected bones to break.  Most hip fractures in the elderly are an indirect result of brittle bones.  The hump or curvature on the back of many of our senior citizens are due to fractures of the spine from osteoporotic vertebrae.

Risk factors

Certain risk factors are linked to the development of osteoporosis and contribute to an individual's
likelihood of developing the disease. Many people with osteoporosis have several risk factors, but others who develop the disease have no known risk factors. There are some you cannot change and others you can.

Risk you cannot change

Gender - Your chances of developing osteoporosis are greater if you are a woman. Women have less bone tissue and lose bone faster than men because of the changes that happen with menopause.

Age - The older you are, the greater your risk of osteoporosis. Your bones become thinner and weaker as you age.

Body size - Small, thin-boned women are at greater risk.

Ethnicity - Caucasian and Asian women are at highest risk.  African American and Hispanic women have a lower but significant risk.

Family history - Fracture risk may be due, in part, to heredity. People whose parents have a history of fractures also seem to have reduced bone mass and may be at risk for fractures.

Risk you can change

Sex hormones - Abnormal absence of menstrual periods (amenorrhea), low estrogen level (menopause), and low testosterone level in men can bring on osteoporosis.

Anorexia nervosa/bulimia - Characterized by an irrational fear of weight gain, this eating disorders increases your risk for osteoporosis.

Calcium and vitamin D intake - A lifetime diet low in calcium and vitamin D makes you more prone to bone loss.

Medication use - Long-term use of glucocorticoids and some anticonvulsants can lead to loss of bone density and fractures.

Lifestyle - An inactive lifestyle or extended bed rest tends to weaken bones.

Cigarette smoking - Cigarettes are bad for bones as well as the heart and lungs.

Alcohol intake - Excessive consumption increases the risk of bone loss and fractures.


To reach optimal peak bone mass and continue building new bone tissue as you age, there are several factors you should consider:

Calcium: An inadequate supply of calcium over a lifetime contributes to the development of osteoporosis. Many published studies show that low calcium intake appears to be associated with low bone mass, rapid bone loss, and high fracture rates. National nutrition surveys show that many people consume less than half the amount of calcium recommended to build and maintain healthy bones. Good sources of calcium include low-fat dairy products, such as milk, yogurt, cheese, and ice cream; dark green, leafy vegetables, such as broccoli, collard greens, bok choy, and spinach; sardines and salmon with bones; tofu; almonds; and foods fortified with calcium, such as orange juice, cereals, and breads. Depending upon how much calcium you get each day from food, you may need to take a calcium supplement. 
Calcium needs change during one's lifetime. The body's demand for calcium is greater during childhood and adolescence, when the skeleton is growing rapidly, and during pregnancy and breastfeeding. Postmenopausal women and older men also need to consume more calcium. Also, as you age, your body becomes less efficient at absorbing calcium and other nutrients. Older adults also are more likely to have chronic medical problems and to use medications that may impair calcium absorption. 
Vitamin D: Vitamin D plays an important role in calcium absorption and in bone health. It is made in the skin through exposure to sunlight. While many people are able to obtain enough vitamin D naturally, studies show that vitamin D production decreases in the elderly, in people who are housebound, and for people in general during the winter. Depending on your situation, you may need to take vitamin D supplements to ensure a daily intake of between 600 to 1000 IU of vitamin D. Massive doses are not recommended unless prescribed by your doctor.

Exercise: Like muscle, bone is living tissue that responds to exercise by becoming stronger. Weight-bearing exercise is the best for your bones because it forces you to work against gravity. Examples include walking, hiking, jogging, stair climbing, weight training, tennis, and dancing.

Smoking: Smoking is bad for your bones as well as for your heart and lungs. Women who smoke have lower levels of estrogen compared to nonsmokers, and they often go through menopause earlier. Smokers also may absorb less calcium from their diets.

Alcohol: Regular consumption of 2 to 3 ounces a day of alcohol may be damaging to the skeleton, even in young women and men. Those who drink heavily are more prone to bone loss and fractures, because of both poor nutrition and increased risk of falling.

Medications that cause bone loss: The long-term use of glucocorticoids (medications prescribed for a wide range of diseases, including arthritis, asthma, Crohn's disease, lupus, and other diseases of the lungs, kidneys, and liver) can lead to a loss of bone density and fractures. Bone loss can also result from long-term treatment with certain antiseizure drugs - such as phenytoin (Dilantin1) and barbiturates; gonadotropin-releasing hormone (GnRH) drugs used to treat endometriosis; excessive use of aluminum-containing antacids; certain cancer treatments; and excessive thyroid hormone. It is important to discuss the use of these drugs with your physician and not to stop or change your medication dose on your own. 
Preventive medications: Various medications are available for preventing and treating osteoporosis


The diagnosis of osteoporosis is done by a bone density study. This is a low dose X-ray study that can be correlated with risk for developing fractures. The reading is given as a comparison of the patient's bone density to that of a healthy 30 year old.

Risk factors

Certain risk factors are linked to the development of osteoporosis and contribute to an individual's
likelihood of developing the disease. Many people with osteoporosis have several risk factors, but others who develop the disease have no known risk factors. There are some you cannot change and others you can.


 A comprehensive osteoporosis treatment program includes a focus on proper nutrition, exercise, and safety issues to prevent falls that may result in fractures. In addition, your physician may prescribe a medication to slow or stop bone loss, increase bone density, and reduce fracture risk.

Nutrition: The foods we eat contain a variety of vitamins, minerals, and other important nutrients that help keep our bodies healthy. All of these nutrients are needed in balanced proportion. In particular, calcium and vitamin D are needed for strong bones, and for your heart, muscles, and nerves to function properly. (See Prevention section for recommended amounts of calcium.)

Exercise: Exercise is an important component of an osteoporosis prevention and treatment program. Exercise not only improves your bone health, but it increases muscle strength, coordination, and balance, and leads to better overall health. While exercise is good for someone with osteoporosis, it should not put any sudden or excessive strain on your bones. As extra insurance against fractures, your doctor can recommend specific exercises to strengthen and support your back.

Therapeutic Medications:

Currently, alendronate, raloxifene, risedronate, and ibandronate are approved by the U. S. Food and Drug Administration (FDA) for preventing and treating postmenopausal osteoporosis. Teriparatide is approved for treating the disease in postmenopausal women and men at high risk for fracture. Estrogen/hormone therapy (ET/HT) is approved for preventing postmenopausal osteoporosis, and calcitonin is approved for treatment. 

Bisphosphonates - Alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva), are medications from the class of drugs called bisphosphonates. Like estrogen and raloxifene, these bisphosphonates are approved for both prevention and treatment of postmenopausal osteoporosis. Another bisphosphonate, zoledronic acid (Reclast), is approved for the treatment of postmenopausal osteoporosis. Alendronate is also approved to treat bone loss that results from glucocorticoid medications like prednisone or cortisone and is approved for treating osteoporosis in men. Risedronate is approved to prevent and treat glucocorticoid-induced osteoporosis and to treat osteoporosis in men. 
Alendronate, risedronate, and zoledronic acid have been shown to increase bone mass and reduce the incidence of spine, hip, and other fractures. Ibandronate has been shown to reduce the incidence of spine fractures.

Alendronate is available in daily and weekly doses. Risedronate is available in daily, weekly, and monthly doses. Ibandronate is available in a monthly dose and as an intravenous injection administered once every three months. Zoledronic acid is available as an intravenous injection administered once yearly.

Side effects for oral bisphosphonates include gastrointestinal problems such as difficulty swallowing, inflammation of the esophagus, and gastric ulcer. 
Side effects for intravenous bisphosphonates include flu-like symptoms, fever, pain in muscles or joints, and headache. These side effects can occur shortly after receiving an infusion and generally stop within two to three days.

There have also been rare reports of osteonecrosis of the jaw and of visual disturbances in people taking oral and intravenous bisphosphonates.

Some bisphosphonates are marketed with calcium and vitamin D supplements. These nutrients are important for everyone, and people should include adequate amounts of them in their diets.

Raloxifene - Raloxifene (Evista) is approved for the prevention and treatment of postmenopausal osteoporosis. It is from a class of drugs called estrogen agonists/antagonists, commonly referred to as selective estrogen receptor modulators (SERMs). Raloxifene appears to prevent bone loss in the spine, hip, and total body. It has beneficial effects on bone mass and bone turnover and can reduce the risk of vertebral fractures. While side effects are not common with raloxifene, those reported include hot flashes and blood clots in the veins, the latter of which is also associated with estrogen therapy. Additional research studies on raloxifene will continue for several more years. 

Calcitonin - Calcitonin (Miacalcin, Fortical) is a naturally occurring hormone involved in calcium regulation and bone metabolism. In women who are at least 5 years past menopause, calcitonin slows bone loss, increases spinal bone density, and may relieve the pain associated with bone fractures. Calcitonin reduces the risk of spinal fractures and may reduce hip fracture risk as well. Studies on fracture reduction are ongoing. Calcitonin is currently available as an injection or nasal spray. While it does not affect other organs or systems in the body, injectable calcitonin may cause an allergic reaction and unpleasant side effects including flushing of the face and hands, frequent urination, nausea, and skin rash. The only side effect reported with nasal calcitonin is nasal irritation. 

Teriparatide - Teriparatide (Forteo) is an injectable form of human parathyroid hormone. It is approved for postmenopausal women and men with osteoporosis who are at high risk for having a fracture. Unlike the other drugs used in osteoporosis, teriparatide acts by stimulating new bone formation in both the spine and the hip. It also reduces the risk of vertebral and nonvertebral fractures in postmenopausal women. In men, teriparatide reduces the risk of vertebral fractures. However, it is not known whether teriparatide reduces the risk of nonvertebral fractures. Side effects include nausea, dizziness and leg cramps. Teriparatide is approved for use for up to 24 months. 
Abaloparatide (Tymlos): is also a parathyroid hormone analog with similar mode of action and efficacy as teriparatide.  It is also given by daily injections.  

Romosozumab (Evenity):  Romosozumab is a monoclonal antibody against sclerosin.  It prevents fractures by increasing the bult up of bone (anabolic action) and decreasing the resorption of bone (anticatabolic action ) .  It is given by injection monthly for 12 months.  It looses potency after a year.  The medication reduces fractures of the spine and hip.  It is contraindicated in persons with history of cardivascular disease or strokes. 

Denosumab (Prolia)- Denosumab is a mononuclear antibody that inhibits osteoclast, the cells that break bone down, from maturing hence preventing bone loss.  It was approved by the FDA for the use in postmenopausal osteoporosis in June of 2010. It must be given by injection to the subcutaneous tissue-similar to an injection of insulin. It is given twice a year. This can be done easily in a doctor’s office. 

Estrogen/Hormone Therapy - Estrogen/hormone therapy (ET/HT) has been shown to reduce bone loss, increase bone density in both the spine and hip, and reduce the risk of spine and hip fractures in postmenopausal women. ET/HT is approved for preventing postmenopausal osteoporosis and is most commonly administered in the form of a pill or skin patch. When estrogen - also known as estrogen therapy or ET - is taken alone, it can increase a woman's risk of developing cancer of the uterine lining (endometrial cancer). To eliminate this risk, physicians prescribe the hormone progestin - also known as hormone therapy or HT - in combination with estrogen for those women who have not had a hysterectomy. Side effects of ET/HT include vaginal bleeding, breast tenderness, mood disturbances, blood clots in the veins, and gallbladder disease.

The Women's Health Initiative, a large Government-funded research study, recently demonstrated that the drug Prempro (estrogen combined with progestin), which is used in hormone therapy, is associated with a modest increase in the risk of breast cancer, stroke, and heart attack. The WHI also demonstrated that in patients who had a hysterectomy, estrogen therapy alone was associated with an increase in the risk of stroke, but not of breast cancer or cardiovascular disease. A large study from the National Cancer Institute indicated that long-term use of estrogen therapy may be associated with an increased risk of ovarian cancer. 
Estrogen therapy is approved for treatment of menopausal symptoms but should be prescribed for the shortest period of time possible. When used solely for the prevention of postmenopausal osteoporosis, any ET/HT regimen should only be considered for women at significant risk of osteoporosis, and nonestrogen medications should be carefully considered first.